Production-scale formulation of inactivated porcine parvovirus (PPV) antigen into a ready-to-use intramuscular injection for gilts and sows starts from a frozen antigen concentrate thawed at 2–8 °C for 18–24 h in a classified cold zone. The thawed bulk is held in single-use bioprocess bags and transferred by peristaltic pump into a jacketed stainless steel mixing vessel chilled to 4–8 °C. Aluminium hydroxide gel adjuvant is added to achieve a final Al³⁺ concentration commonly targeted at 0.8–1.5 mg per 2 mL dose, while the PPV antigen load is set by the pre-inactivation titre and released relative potency. A typical pre-inactivation titre of not less than 10⁷.⁰ TCID₅₀ per millilitre is commonly declared in the marketing authorisation dossier, and the post-adsorption supernatant haemagglutination titre must remain below a batch-specific threshold to confirm adequate binding. Mixing is performed with a low-shear impeller at 60–100 rpm for 30–45 min; vortex formation is avoided because excessive shear can desorb antigen from the aluminium hydroxide surface. After adsorption, the batch is adjusted to pH 6.8–7.2 with phosphate-controlled buffer to prevent ligand exchange on the aluminium hydroxide surface. The finished terminal product is a sterile aqueous suspension filled at 2 mL per Type I glass vial or pre-filled syringe under aseptic conditions. Release testing follows Ph. Eur. monograph 0965 and 9 CFR 113.111, with sterility by Ph. Eur. 2.6.1, bacterial endotoxins by Ph. Eur. 2.6.14, and final container closure integrity verified routinely. Published data on adsorption kinetics in this specific PPV configuration is limited; therefore each manufacturing site must qualify the exact aluminium hydroxide antigen ratio against field-efficacy data rather than relying on a universal formula.

When Inactivated PPV Antigen Is Lyophilized as a Powder Intermediate for Polyvalent Formulation

Lyophilized PPV antigen concentrates serve as a long-term intermediate rather than as a final registered parenteral dosage form in most jurisdictions. The antigen suspension is formulated with sucrose or trehalose at 5–10 % w/v, filled into partially stoppered Type I glass vials or stainless steel trays, and loaded onto a shelf freeze-dryer. A conservative cycle brings the product to −40 °C and holds for at least 4 h to ensure complete solidification of the amorphous phase. Primary drying is conducted at a shelf temperature of −20 °C and chamber pressure of 50–80 µbar for 24–48 h, controlled by capacitance manometer and comparative pressure measurement to avoid product temperature exceeding the critical glass transition temperature of the frozen concentrate. Secondary drying is ramped to 20–25 °C for 6–12 h until residual moisture by Karl Fischer titration is 1.0–3.0 %. The terminal lyophilized cake is a sterile powder intermediate that can be shipped and reconstituted with Water for Injection or a buffered diluent for downstream blending with adjuvanted bacterins or toxoids. A failure mode observed on production lines is microcollapse of the cake when the shelf temperature exceeds the collapse temperature by as little as 2–3 °C, resulting in increased reconstitution time beyond 10 min and non-uniform antigen distribution. Ph. Eur. sterility testing 2.6.1, reconstitution time, and visual appearance are release tests; viral potency is reassessed after reconstitution using haemagglutination titration or an appropriate ELISA calibrated against a reference vaccine. Published data for marketed PPV final freeze-dried injections is limited; the powder is therefore regarded as a stability-critical intermediate, not a final sterile dosage form for direct sale to end users.

Polyvalent inactivated vaccines containing PPV antigen plus Erysipelothrix rhusiopathiae bacterin and Leptospira interrogans serovar bacterins create a competitive adsorption environment on aluminium-based adjuvants that must be managed by sequential addition under controlled temperature. The PPV antigen is generally adsorbed first at 4–8 °C because its non-enveloped capsid binds less strongly than larger bacterial antigens under high protein load. After 15 min of gentle mixing at 50–80 rpm, Leptospira bacterins are introduced, followed by the Erysipelothrix component after a further 15 min; this order is not a default parameter and must be confirmed by Langmuir adsorption isotherms and desorption studies using the specific aluminium hydroxide or aluminium phosphate grain size distribution. The final pH is maintained at 6.8–7.2, and the total protein-to-adjuvant ratio is controlled so that the supernatant antigen concentration after centrifugation remains below the batch-specific acceptance limit. Failure to control this ratio can result in delayed desorption and reduced seroconversion in gilts. The terminal product is a sterile 2 mL injectable suspension filled into Type I glass vials; the combined vaccine is released against 9 CFR 113.111 for the PPV fraction and the relevant bacterin monographs for the bacterial fractions. Batch-to-batch variance in host-cell DNA and bacterial endotoxin requires pre-blend qualification of each monovalent bulk; a polyvalent blend that passes sterility but fails the PPV fraction potency test cannot be reworked and must be destroyed. This is a deep-dive manufacturing constraint because the adsorption system has no practical in-process potency test that gives a real-time release decision; the final PPV potency is only known after the batch is filled and tested.

What Limits Sterile Filtration Integrity When Processing a 20–25 nm Non-Enveloped Virus Particle?

PPV antigen concentrates are among the few veterinary vaccine intermediates in which the virus particle diameter of 20–25 nm is smaller than the nominal pore size of a 0.22 µm sterilizing-grade membrane. This allows a bioburden reduction filtration step that is not feasible for larger enveloped viruses. The process typically uses a 0.45 µm polypropylene or PVDF prefilter followed by a 0.22 µm PVDF final filter, with differential pressure held at 0.5–1.0 bar and flux maintained below 100 L/m²/h to limit concentration polarisation. However, the virus is not retained by the membrane, so the step is not a terminal sterilisation method; final sterility depends on aseptic filling and filter integrity testing performed before and after production per ASTM F838 or equivalent. Fouling is the principal failure mode, driven by residual host-cell proteins, cell debris, and DNA rather than by the virion itself. A nuclease digestion step is often applied to reduce host genomic DNA and lower viscosity; the effective DNA concentration is monitored by qPCR and is typically reduced to below 10 ng per dose in human-use analogues, although veterinary marketing authorisations may specify a different bound. The filtered antigen solution is then transferred to a chilled hold vessel at 2–8 °C before adjuvant adsorption. Release tests include bioburden before filtration, endotoxin by Ph. Eur. 2.6.14, and host-cell protein by ELISA; the virus particle integrity is confirmed by negative-stain electron microscopy or dynamic light scattering to rule out aggregation above 80–100 nm that would indicate filter shear damage or formulation instability. The terminal material from this step is a clarified antigen solution intended for subsequent adjuvant adsorption or lyophilization, not a final injectable product.

Capsule, tablet, granule, and drinking-water premix formats are not recognised downstream presentations for inactivated PPV antigen in any jurisdiction with a published veterinary vaccine monograph. The biological target of PPV vaccination is systemic IgG production and subsequent transplacental antibody transfer to fetuses during the first half of gestation; this requires parenteral delivery of adjuvanted antigen to professional antigen-presenting cells in muscle or subcutaneous tissue. Orally delivered inactivated PPV antigen is exposed to gastric acid at pH 1.5–3.5 and pancreatic proteases, which degrade the non-enveloped capsid and remove surface epitopes required for neutralising antibody induction. Even if an enteric-coated capsule protected the antigen through the stomach, the intestinal M-cell uptake rate for soluble non-adjuvanted inactivated viral protein is insufficient to generate the immune response needed for reproductive protection. No standard process exists for tableting or encapsulating this antigen without destroying its haemagglutination titre; dry granulation and direct compression impose shear and compression forces that have not been validated for PPV capsid integrity. Therefore these oral solid dosage forms are not listed as terminal products in this applications profile, and formulators are advised to maintain the antigen in liquid suspension or lyophilized powder for parenteral use only. This limitation is a regulatory and biological reality rather than a formulation gap.

Parenteral Depot Microparticle Powder and Oil-in-Water Emulsion Evaluation Routes

Investigational formulations of PPV antigen in poly(lactic-co-glycolic acid) (PLGA) microspheres are prepared by a water-in-oil-in-water double emulsion method. The primary emulsion is formed by dispersing the antigen solution into dichloromethane containing PLGA 50:50 at a polymer concentration of 10–20 % w/v, followed by high-shear homogenisation at 10,000–15,000 rpm with polyvinyl alcohol as the external aqueous stabiliser. The resulting microparticle powder is recovered after solvent evaporation and lyophilization; residual dichloromethane is controlled to Class 3 solvent limits and verified by gas chromatography. Oil-in-water emulsion adjuvanted trials use squalene or light mineral oil as the oil phase with polysorbate 80 as surfactant, but published data for a commercial PPV oil-in-water product is limited. These depot routes are not standard veterinary practice and do not have a compendial monograph; they are evaluated for single-dose immunisation programmes where handling of multiple injections on large breeding units is a production bottleneck. Terminal products under investigation are sterile injectable powders for reconstitution or emulsion injections; release testing must still comply with 9 CFR 113.111 for the PPV fraction if the product is to be registered in the United States. Formulators must confirm that the encapsulation process does not denature the capsid by measuring the ratio of haemagglutination titre before and after processing; a loss greater than 0.5 log₁₀ is usually considered unacceptable for further development. The primary limitation is the absence of commercial-scale validated processes; published data for this specific PPV configuration is limited.